Compare KODK & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KODK | ABUS |
|---|---|---|
| Founded | 1880 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 982.9M | 836.0M |
| IPO Year | 1994 | 2008 |
| Metric | KODK | ABUS |
|---|---|---|
| Price | $8.09 | $4.08 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 845.2K | ★ 2.3M |
| Earning Date | 11-03-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.26 |
| EPS | 0.11 | ★ 1.13 |
| Revenue | ★ $4,114,000,000.00 | $14,083,000.00 |
| Revenue This Year | $10.63 | $1,208.75 |
| Revenue Next Year | $6.60 | N/A |
| P/E Ratio | $77.32 | ★ $3.59 |
| Revenue Growth | N/A | ★ 128.21 |
| 52 Week Low | $6.54 | $3.50 |
| 52 Week High | $14.87 | $5.45 |
| Indicator | KODK | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 39.83 | 47.64 |
| Support Level | $7.43 | N/A |
| Resistance Level | $10.11 | $4.52 |
| Average True Range (ATR) | 0.41 | 0.21 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 32.29 | 60.76 |
Eastman Kodak Co is a United States-based company. It operates through several business segments; Print, Brand, and Advanced Materials and Chemicals. The Print segment which derives the majority of revenue includes products like digital offset plate offerings and computer-to-plate imaging solutions, high-quality digital printing solutions using electrically charged toner-based technology, production press systems, consumables, inkjet components, software and services. Geographically, the company generates revenue from the United States, Canada, Europe, Middle East and Africa, Asia Pacific, and Latin America.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.